Immunotherapy duo shows promise in shrinking aggressive colorectal tumors before surgery
NCT ID NCT07160647
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study tests two immunotherapy drugs, iparomlimab and tuvonralimab, given before surgery to people with a specific genetic type of colorectal cancer (MSI-H/dMMR). The goal is to see if this combination can completely eliminate the tumor before surgery. About 29 adults with stage IIB-III rectal cancer will participate, and researchers will also study tissue samples to better understand who benefits most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DMMR/MSI-H-TYPE RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine,
Hangzhou, Zhejiang, 310016, China
Conditions
Explore the condition pages connected to this study.